Download Shionogi announces agreements on collaborative research and a

Shionogi announces agreements on collaborative research and a right of first refusal
aimed at novel anti-infective drug discovery with NB Health Laboratory
Osaka, Japan, July 15, 2016 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President &
CEO: Isao Teshirogi, Ph.D.; hereinafter called “Shionogi”) and NB Health Laboratory Co. Ltd.
(Head Office: Sapporo, Japan; President: Kiyoshi Takayama, Ph.D.; hereinafter called
“NBHL”), enter into research collaboration aimed at discovery of drug targets to develop novel
anti-infective drug candidates. Also, Shionogi announces agreements on a right of first refusal
to join the research collaboration which NBHL and Hokkaido University (President: Keizo
Yamaguchi) promote in infectious disease area.
Shionogi provides NBHL with a floor of Shionogi-owned research facility, Shionogi
Innovation Center for Drug Discovery (hereinafter called “SIC”) in Hokkaido University and
promotes collaborative research aimed at small-molecule drug discovery for infectious
diseases. Also, Shionogi obtains a right of first refusal to join the collaborative research which
NBHL and Hokkaido University promote aimed at drug discovery for infectious diseases at
SIC.
Shionogi had been promoting the industry-academia collaboration project “Innovations in
Future Drug Discovery and Medicine Care” with Hokkaido University for the past 10 years
(July 2006 - March 2016). Shionogi achieve research results such as drug efficacy evaluation
of novel anti-influenza drug (S-033188), new target discovery for metabolic syndrome in lipid
biology research, and new biomarker discovery for liver disease in glycomics research, making
use of academia seeds, technologies and facilities. After this project, Shionogi and NBHL join
the Center of Life Innovation (Head of Center: Katsumi Maenaka, Ph.D.) which Hokkaido
University newly organized. Shionogi promotes industry-academia and industry-industry
collaboration in our core therapeutic area, infectious diseases.
Shionogi & Co., Ltd. has been researching, developing and distributing innovative
infectious disease drugs for more than fifty years. Shionogi is a major research-driven
pharmaceutical company dedicated to placing the highest value on patients. In addition to
in-house-research activity, Shionogi is focusing on utilization of outer resources from
collaborative research with partners such as academia and other companies in order to
contribute to patients.
For further information, contact:
Corporate Communications Department
Shionogi & Co., Ltd.
Telephone: +81-6-6209-7885
1
About NB Health Laboratory Co. Ltd. (NBHL)
NBHL is a biotechnology company with a core technology for antibody production,
MoGRAA™ discovery engine, dedicated to generating new drug candidates for respiratory
diseases, infectious diseases, chronic inflammation and central nervous system disorders,
while NBHL also provides state-of-the-art drug discovery platform.
By continuously striving to improve its drug discovery competence and technology for creation
of “new concepts of medicines”, and with an awareness of the views of patients and clinicians,
NBHL accelerates its R&D to deliver medicines truly desired to the clinical practice.
Founded in July, 2006
Headquarters Address: Sapporo, Hokkaido, Japan
Founder and President: Kiyoshi Takayama, Ph.D.
Contact personnel: Tomoko Shimizu, Director of BD
TEL: +81-11-708-7156
URL: http://www.nbhl.co.jp/
2